Deutsche Bank Aktiengesellschaft Cuts R1 RCM (NASDAQ:RCM) Price Target to $28.00

R1 RCM (NASDAQ:RCMGet Rating) had its price target reduced by stock analysts at Deutsche Bank Aktiengesellschaft from $30.00 to $28.00 in a research note issued on Tuesday, The Fly reports. Deutsche Bank Aktiengesellschaft’s target price points to a potential upside of 46.52% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird increased their target price on shares of R1 RCM from $29.00 to $32.00 in a research report on Thursday, March 3rd. Zacks Investment Research upgraded shares of R1 RCM from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research note on Thursday, April 21st. Finally, Guggenheim assumed coverage on shares of R1 RCM in a research note on Wednesday, April 13th. They issued a “neutral” rating for the company. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $29.25.

Shares of R1 RCM stock opened at $19.11 on Tuesday. The company has a fifty day moving average of $25.25 and a 200 day moving average of $24.55. R1 RCM has a fifty-two week low of $18.71 and a fifty-two week high of $27.86. The company has a market capitalization of $5.32 billion, a P/E ratio of -8.89, a P/E/G ratio of 2.46 and a beta of 0.86. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.43 and a current ratio of 1.43.

R1 RCM (NASDAQ:RCMGet Rating) last issued its quarterly earnings data on Monday, May 9th. The healthcare provider reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.04). R1 RCM had a return on equity of 30.22% and a net margin of 6.59%. The company had revenue of $385.70 million for the quarter, compared to analysts’ expectations of $384.18 million. During the same quarter last year, the company earned ($2.37) earnings per share. The company’s revenue for the quarter was up 12.6% compared to the same quarter last year. Analysts forecast that R1 RCM will post 0.46 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC bought a new stake in shares of R1 RCM in the 1st quarter worth approximately $295,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of R1 RCM during the 1st quarter valued at about $129,000. Swiss National Bank boosted its position in shares of R1 RCM by 7.0% during the 1st quarter. Swiss National Bank now owns 295,400 shares of the healthcare provider’s stock valued at $7,905,000 after purchasing an additional 19,300 shares in the last quarter. Waratah Capital Advisors Ltd. purchased a new stake in R1 RCM during the first quarter valued at about $681,000. Finally, Teacher Retirement System of Texas lifted its stake in R1 RCM by 7.2% during the first quarter. Teacher Retirement System of Texas now owns 25,980 shares of the healthcare provider’s stock valued at $695,000 after buying an additional 1,745 shares in the last quarter. 41.97% of the stock is currently owned by institutional investors.

About R1 RCM (Get Rating)

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.

Featured Stories

The Fly logo

Analyst Recommendations for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with's FREE daily email newsletter.